

| | | |
|---|---------------------------------|--------------------------|
| Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | Atty. Docket No. 070050.2897 | Serial No. 10/809,312 |
| | Applicant Greene, et al. | |
| | Filing Date 03/24/2004 | Group 1636 |
| | Examiner Laura L. McGillem | |
| | | |

| Exam Initial | No. | OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.) |
|-----------------|-----|--|
| | 1. | Nikkah, et al., "Intranigral fetal dopamine grafts induce behavioral compensation in the rat Parkinson model." J Neurosci. 1994 Jun;14(6):3449-61. |
| | 2. | Defer, et al., "Long-term outcome of unilaterally transplanted parkinsonian patients. I. Clinical approach." Brain. 1996 Feb;119 (Pt 1):41-50. |
| | 3. | Zecca, et al., "Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia." Blood. 2001 Jun 15;97(12):3995-7. |
| | 4. | Carroll, et al., "The role of natural killer cells in adenovirus-mediated p53 gene therapy." Mol Cancer Ther. 2001 Nov;1(1):49-60. |

NY02:608179.1

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.